Journal
DIABETIC MEDICINE
Volume 30, Issue 4, Pages e149-e150Publisher
WILEY-BLACKWELL
DOI: 10.1111/dme.12134
Keywords
-
Categories
Ask authors/readers for more resources
Background Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to be generally well tolerated. However, angioedema has been reported as one of the rare adverse events of these drugs. Case report We report a case in which angioedema induced by vildagliptin disappeared after changing to another DPP-4 inhibitor, alogliptin. Discussion Our case suggests that there is a difference in the risk of angioedema among DPP-4 inhibitors. To clarify this possibility, further investigation on the risk of angioedema among DPP-4 inhibitors is warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available